Earnings ·
REGENXBIO Inc. reported second quarter 2026 financial results and operational highlights for the period ended June 30…
RGNXREGENXBIO Inc.
REGENXBIO Inc. reported second quarter 2026 financial results and operational highlights for the period ended June 30, 2026. The company achieved net income of $22.7 million, or $0.43 per share, compared to a net loss of $70.9 million in the prior year period. Revenues increased to $108.0 million from $21.4 million, driven by a $100.0 million development milestone payment from AbbVie for dosing the first patient in the NAAVIGATE diabetic retinopathy study. The company received over $200 million in new capital in July 2026, including approximately $108 million in net proceeds from an underwritten public offering and the AbbVie milestone payment, extending its cash runway into Q4 2027. Key clinical updates include the Phase III AFFINITY DUCHENNE trial meeting its primary endpoint with high statistical significance (p<0.0001) and a BLA submission for RGX-202 on track for Q3 2026 initiation. REGENXBIO is a biotechnology company focused on developing AAV gene therapies for rare, retinal, neuromuscular, and neurodegenerative diseases.